D75.82

Clinical Causes: Heparin therapy, especially when used over a prolonged period or in high doses Development of antibodies against complexes formed between heparin and platelet factor 4 (PF4) Genetic predispositions that may influence immune response Type of heparin administered, with unfractionated heparin carrying a higher risk compared to low molecular weight heparin

Key Symptoms: Sudden decrease in platelet count (thrombocytopenia) Signs of blood clots, such as redness, swelling, warmth, and pain in limbs Unusual blood clots in other parts of the body, including lungs, brain, or heart Skin reactions at the injection site, including redness or rash Possible signs of organ dysfunction or ischemia if blood clots obstruct blood flow

Diagnosis Path: Diagnosis of HIT involves a combination of clinical assessment and laboratory testing. Healthcare providers typically look for a significant drop in platelet count within 5 to 14 days of starting heparin therapy. Confirmatory tests include the detection of anti-PF4/heparin antibodies using immunoassays. In certain cases, functional assays are performed to assess the platelet activation response. It's essential to rule out other causes of thrombocytopenia and thrombosis during diagnosis.

Treatment Protocols: Managing HIT requires immediate cessation of all heparin products and avoiding further exposure. Alternative anticoagulants, such as direct thrombin inhibitors or fondaparinux, are often used to prevent or treat blood clots. Monitoring platelet counts closely is crucial, and in some cases, plasma exchange or immunomodulatory therapies may be considered. Early recognition and appropriate management are vital to reduce the risk of severe complications, including life-threatening clotting events.